Viatris has been granted a patent for (R)-4-(1-(1-(4-(trifluoromethyl)benzyl) pyrrodiline-2-carboxamide) cyclopropyl benzoic acid (Compound 1) or a salt thereof. The patent also covers methods for obtaining the compound and its use as an EP4 receptor antagonist in the treatment of pathologies involving prostaglandin E2 (PGE2) activities. GlobalData’s report on Viatris gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Viatris, Cancer treatment biomarkers was a key innovation area identified from patents. Viatris's grant share as of September 2023 was 57%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for compound 1 as ep4 receptor antagonist
A recently granted patent (Publication Number: US11718582B2) discloses a compound called (R)-4-(1-(1-(4-(trifluoromethyl)benzyl) pyrrodiline-2-carboxamide) cyclopropyl benzoic acid (Compound 1), along with various salts of the compound. The patent also describes a process for preparing Compound 1 or its salts.
The compound and its salts are claimed in the patent, with specific mentions of sodium salt, lithium salt, and hydrochloride salt. The process for preparing Compound 1 or its salts involves several steps. In one embodiment, the process includes forming an amide intermediate by reacting (tert-butoxycarbonyl)-D-proline with methyl 4-(1-aminocyclopropyl) using a coupling agent. The coupling agent used in this step is 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. Subsequent steps involve the use of specific acids, bases, and strong bases to obtain the desired compound or salt.
The patent also covers the use of Compound 1 or its salts in pharmaceutical compositions. These compositions include the compound or salt along with pharmaceutically acceptable excipients. Additionally, the patent describes a method for the treatment of pathologies involving the activity of prostaglandin E2 (PGE2) in their pathogenesis. The method involves administering Compound 1 or its salt as an EP4 receptor antagonist. The pathologies that can be treated using this method include rheumatoid arthritis, spondylarthritis, psoriatic arthritis, ankylosing spondylitis, arthrosis, acute and chronic pain due to inflammation, osteoarthritis pain, arthritis pain with immunologic etiology, and rheumatoid arthritis. The method can also be applied to treat eye diseases, endometriosis, retinopathy of prematurity (ROP), proliferative diabetic retinopathy, and age-related macular degeneration (AMD).
In summary, the granted patent discloses a compound called (R)-4-(1-(1-(4-(trifluoromethyl)benzyl) pyrrodiline-2-carboxamide) cyclopropyl benzoic acid (Compound 1) and its salts, along with a process for their preparation. The patent also covers the use of Compound 1 or its salts in pharmaceutical compositions and their application as EP4 receptor antagonists for the treatment of various pathologies involving the activity of prostaglandin E2 (PGE2).
To know more about GlobalData’s detailed insights on Viatris, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
